Last 12 months
Inside the activity.
0 purchase rows · 46 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 15 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2020 Filed Feb 12, 2020 22:00 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionCommon Stock | 127 | $65.36 | $8,300.72 |
DisclosureSEC source: 0001209191-20-008842 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This includes an aggregate of 15,249 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:48 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,542 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-20-007561 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,542 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:48 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
SaleCommon Stock | 17,542 | $75.97 | $1,332,665.74 |
DisclosureSEC source: 0001209191-20-007561 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,308 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $74.56 - $76.46 F4 · balance_after: This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:48 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Exercise / conversionCommon Stock | 17,542 | $18.32 | $321,369.44 |
DisclosureSEC source: 0001209191-20-007561 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:30 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 64 | $78.24 | $5,007.36 |
DisclosureSEC source: 0001209191-20-004992 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,557 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 14,808 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:12 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 64 | $78.24 | $5,007.36 |
DisclosureSEC source: 0001209191-20-004985 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,351 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,067 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:44 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,290 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004492 · doc4.xml · derivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,290 Underlying: Common Stock · 2,290 shares Expires 2030-01-16 F3 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:44 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantCommon Stock | 4,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004492 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,324 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 17, 2020, subject to Paul Trower's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 17, 2020 Restricted Stock Unit Grant, this includes an aggregate of 11,011 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:39 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004487 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F3 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:39 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantCommon Stock | 11,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004487 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,461 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 17, 2020, subject to Barry Flannelly's continued service with the issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 17, 2020 Restricted Stock Unit Grant, this includes an aggregate of 25,433 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:29 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 59 | $80.50 | $4,749.50 |
DisclosureSEC source: 0001209191-20-004485 · doc4.xml · nonDerivative · entry 2 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,621 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: Including the January 17, 2020 Restricted Stock Unit Grant, this includes an aggregate of 15,917 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:29 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
GrantCommon Stock | 5,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004485 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,680 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Morrissey's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:27 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 59 | $80.50 | $4,749.50 |
DisclosureSEC source: 0001209191-20-004480 · doc4.xml · nonDerivative · entry 2 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,415 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: Including the January 17, 2020 Restricted Stock Unit Grant, this includes an aggregate of 15,917 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:27 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
GrantCommon Stock | 5,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004480 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,474 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Dickinson's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:24 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
GrantEmployee Stock Option (right to buy) · Derivative | 96,328 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004474 · doc4.xml · derivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,328 Underlying: Common Stock · 96,328 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:22 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004472 · doc4.xml · derivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:20 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004466 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:18 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004462 · doc4.xml · derivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:16 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004455 · doc4.xml · derivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:13 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004450 · doc4.xml · derivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:11 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004448 · doc4.xml · derivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:20 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $64.55 | $0.00 |
DisclosureSEC source: 0001209191-20-003970 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,139 Underlying: Common Stock · 2,500 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:20 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 2,500 | $81.12 | $202,800.00 |
DisclosureSEC source: 0001209191-20-003970 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,612 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:20 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 2,500 | $64.55 | $161,375.00 |
DisclosureSEC source: 0001209191-20-003970 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 21:54 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 127 | $0.00 Strike: $65.36 | $0.00 |
DisclosureSEC source: 0001209191-20-003319 · doc4.xml · derivative · entry 2 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,460 Underlying: Common Stock · 127 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning April 9, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 21:54 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionCommon Stock | 127 | $65.36 | $8,300.72 |
DisclosureSEC source: 0001209191-20-003319 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This includes an aggregate of 15,249 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 22:05 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 111 | $77.34 | $8,584.74 |
DisclosureSEC source: 0001209191-20-002556 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,939 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of resticted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 11,207 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 00:24 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 111 | $77.34 | $8,584.74 |
DisclosureSEC source: 0001209191-20-002626 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,733 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of resticted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 11,207 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:20 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
Tax withholdingCommon Stock | 28,345 | $85.97 | $2,436,819.65 |
DisclosureSEC source: 0001209191-20-000931 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,851 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table 1 as common stock, which withholding was not a market transaction by the Reporting Person. F2 · balance_after: This includes an aggregate of 67,617 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:09 UTC |
Clancy Paul JDirector
|
GrantCommon Stock | 231 | $87.32 | $20,170.92 |
DisclosureSEC source: 0001209191-20-000810 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,457 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:12 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 196 | $87.32 | $17,114.72 |
DisclosureSEC source: 0001209191-20-000850 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:15 UTC |
FOUSE JACQUALYN ADirector
|
GrantCommon Stock | 218 | $87.32 | $19,035.76 |
DisclosureSEC source: 0001209191-20-000886 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,049 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:05 UTC |
BIENAIME JEAN JACQUESDirector
|
GrantCommon Stock | 190 | $87.32 | $16,590.80 |
DisclosureSEC source: 0001209191-20-000773 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,464 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:07 UTC |
BROOKE PAUL ADirector
|
GrantCommon Stock | 264 | $87.32 | $23,052.48 |
DisclosureSEC source: 0001209191-20-000791 · doc4.xml · nonDerivative · entry 1 BROOKE PAUL A · CIK 0001175940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,584 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:01 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 316 | $87.32 | $27,593.12 |
DisclosureSEC source: 0001638599-20-000014 · doc4_6450.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 29,291,523 F4 · ownership.nature: 316 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F7 · ownership.nature: Includes beneficial ownership of 4,050 shares previously issued pursuant to the Stock Incentive Plan in lieu of director retainer fees, 135,000 shares received previously from exercise of 135,000 stock options of the Issuer and 1,520 restricted stock units payable solely in Common Stock that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which each of the Funds may be deemed to own a portion. F8 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock of the Issuer reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 316 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:01 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 316 | $87.32 | $27,593.12 |
DisclosureSEC source: 0001638599-20-000014 · doc4_6450.xml · nonDerivative · entry 4 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,827,756 F4 · ownership.nature: 316 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F6 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F7 · ownership.nature: Includes beneficial ownership of 4,050 shares previously issued pursuant to the Stock Incentive Plan in lieu of director retainer fees, 135,000 shares received previously from exercise of 135,000 stock options of the Issuer and 1,520 restricted stock units payable solely in Common Stock that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which each of the Funds may be deemed to own a portion. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 316 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:52 UTC |
HARRIGAN EDMUNDDirector
|
GrantNon-Qualified Stock Option · Derivative | 4,360 | $0.00 Strike: $91.31 | $0.00 |
DisclosureSEC source: 0001209191-19-061321 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,360 Underlying: Common Stock · 4,360 shares Expires 2029-12-16 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:52 UTC |
HARRIGAN EDMUNDDirector
|
GrantCommon Stock | 462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061321 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:59 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $64.55 | $0.00 |
DisclosureSEC source: 0001209191-19-061156 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,639 Underlying: Common Stock · 2,500 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:59 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 2,500 | $91.61 | $229,025.00 |
DisclosureSEC source: 0001209191-19-061156 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,612 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:59 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 2,500 | $64.55 | $161,375.00 |
DisclosureSEC source: 0001209191-19-061156 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 21:35 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 77 | $0.00 Strike: $65.36 | $0.00 |
DisclosureSEC source: 0001209191-19-060663 · doc4.xml · derivative · entry 2 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,587 Underlying: Common Stock · 77 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning April 9, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 21:35 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionCommon Stock | 77 | $65.36 | $5,032.72 |
DisclosureSEC source: 0001209191-19-060663 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This includes an aggregate of 15,249 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 21:36 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
Tax withholdingCommon Stock | 533 | $95.72 | $51,018.76 |
DisclosureSEC source: 0001209191-19-060228 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,106 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 11,920 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:32 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,835 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · derivative · entry 6 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,542 Underlying: Common Stock · 16,835 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:32 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
SaleCommon Stock | 16,835 | $95.00 | $1,599,325.00 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · nonDerivative · entry 4 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,308 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:32 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Exercise / conversionCommon Stock | 16,835 | $18.32 | $308,417.20 |
DisclosureSEC source: 0001209191-19-058714 · doc4.xml · nonDerivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:25 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,366 | $0.00 Strike: $72.86 | $0.00 |
DisclosureSEC source: 0001209191-19-058709 · doc4.xml · derivative · entry 6 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,732 Underlying: Common Stock · 7,366 shares Expires 2023-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning May 9, 2016, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:25 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
SaleCommon Stock | 7,366 | $95.00 | $699,770.00 |
DisclosureSEC source: 0001209191-19-058709 · doc4.xml · nonDerivative · entry 4 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,609 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 12,562 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:25 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
Exercise / conversionCommon Stock | 7,366 | $72.86 | $536,686.76 |
DisclosureSEC source: 0001209191-19-058709 · doc4.xml · nonDerivative · entry 3 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.